[an error occurred while processing this directive] | [an error occurred while processing this directive]
Research status and progress on exosomes in the diagnosis and treatment of malignant glioma
Tang Shaohua,Yin Jun,Wang Weidong,Lang Jinyi
Southwest Medical University,Luzhou 646000,China (Tang SH);Department of Radiotherapy,Sichuan Cancer Hospital& Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China (Tang SH,Yin J,Wang WD,Lang JY)
Abstract In recent years, exosomes has gradually captivated widespread attention. It plays a crucial role in the proliferation, differentiation and metastasis of malignant tumors. As nanosized vesicles,exosomes can penetrate through the blood-brain barrier. Thus,exosomes may be a novel tool for the diagnosis and treatment of malignant glioma. In this paper, 57 relevant literatures were reviewed to summarize the research status and progress on the role of exosomes in the incidence, progression, liquid biopsy, prognosis evaluation and clinical therapy of malignant glioma.
Tang Shaohua,Yin Jun,Wang Weidong et al. Research status and progress on exosomes in the diagnosis and treatment of malignant glioma[J]. Chinese Journal of Radiation Oncology, 2018, 27(4): 425-429.
Tang Shaohua,Yin Jun,Wang Weidong et al. Research status and progress on exosomes in the diagnosis and treatment of malignant glioma[J]. Chinese Journal of Radiation Oncology, 2018, 27(4): 425-429.
[1] De Robles P,Fiest KM,Frolkis AD,et al. The worldwide incidence and prevalence of primary brain tumors:a systematic review and meta-analysis[J].Neuro Oncol,2015,17(6):776-783.DOI:10.1093/neuonc/nou283. [2] Pan BT,Johnstone RM.Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro:selective externalization of the receptor[J].Cell,1983,33(3):967-978.DOI:10.1016/0092-8674(83)90040-5. [3] Johnstone RM,Adam M,Hammond JR,et al. Vesicle formation during reticulocyte maturation.association of plasma membrane activities with released vesicles (exosomes)[J].J Biol Chem,1987,262(19):9412-9420. [4] Sun Y,Liu J.Potential of cancer cell-derived exosomes in clinical application:a review of recent research advances[J].Clin Ther,2014,36(6):863-872.DOI:10.1016/j.clinthera.2014.04.018. [5] Raposo G,Stoorvogel W.Extracellular vesicles:exosomes,microvesicles,and friends[J].J Cell Biol,2013,200(4):373-383.DOI:10.1083/jcb.201211138. [6] Balaj L,Lessard R,Dai LX,et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences[J].Nat Commun,2011,2:180.DOI:10.1038/ncomms1180. [7] Skog J,Wurdinger T,Van Rijn S,et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers[J].Nat Cell Biol,2008,10(12):1470-1476.DOI:10.1038/ncb1800. [8] Théry C,Ostrowski M,Segura E.Membrane vesicles as conveyors of immune responses[J].Nat Rev Immunol,2009,9(8):581-593.DOI:10.1038/nri2567. [9] Sana J,Hajduch M,Michalek J,et al. MicroRNAs and glioblastoma:roles in core signalling pathways and potential clinical implications[J].J Cell Mol Med,2011,15(8):1636-1644.DOI:10.1111/j.1582-4934.2011.01317.x. [10] Kosaka N,Iguchi H,Hagiwara K,et al. Neutral sphingomyelinase 2(nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis[J].J Biol Chem,2013,288(15):10849-10859.DOI:10.1074/jbc. M112.446831. [11] Wang JH,Zheng YJ,Zhao M.Exosome-based cancer therapy:implication for targeting cancer stem cells[J].Front Pharmacol,2016,7:533.DOI:10.3389/fphar.2016.00533. [12] Cooper JM,Wiklander PBO,Nordin JZ,et al. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice[J].Mov Disord,2014,29(12):1476-1485.DOI:10.1002/mds.25978. [13] Dang XT,Zeng XR.Targeted therapeutic delivery using engineered exosomes and its applications in cardiovascular diseases[J].Gene,2016,575(2 Pt 2):377-384.DOI:10.1016/j.gene.2015.08.067. [14] Kucharzewska P,Christianson HC,Welch JE,et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development[J].Proc Natl Acad Sci USA,2013,110(18):7312-7317.DOI:10.1073/pnas.1220998110. [15] Yang JK,Yang JP,Tong J,et al. Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma[J].J Neurooncol,2017,131(2):255-265.DOI:10.1007/s11060-016-2308-5. [16] Hellwinkel JE,Redzic JS,Harland TA,et al. Glioma-derived extracellular vesicles selectively suppress immune responses[J].Neuro Oncol,2016,18(4):497-506.DOI:10.1093/neuonc/nov170. [17] Liu ZM,Wang YB,Yuan XH.Exosomes from murine-derived GL26 cells promote glioblastoma tumor growth by reducing number and function of 8+T cells[J].Asian Pac J Cancer Prev,2013,14(1):309-314.DOI:10.7314/apjcp.2013.14.1.309. [18] Hanahan D,Weinberg RA.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674.DOI:10.1016/j.cell.2011.02.013. [19] Roma-Rodrigues C,Fernandes AR,Baptista PV.Exosome in tumour microenvironment:overview of the crosstalk between normal and cancer cells[J].Biol Med Res Int,2014,2014:179486.DOI:10.1155/2014/179486. [20] Dubois LG,Campanati L,Righy C,et al. Gliomas and the vascular fragility of the blood brain barrier[J].Front Cell Neurosci,2014,8:418.DOI:10.3389/fncel.2014.00418. [21] Filipazzi P,Burdek M,Villa A,et al. Recent advances on the role of tumor exosomes in immunosuppression and disease progression[J].Semin Cancer Biol,2012,22(4):342-349.DOI:10.1016/j.semcancer.2012.02.005. [22] Al-Nedawi K,Meehan B,Micallef J,et al. Intercellular transfer of the oncogenic receptor EGFRvⅢ by microvesicles derived from tumour cells[J].Nat Cell Biol,2008,10(5):619-624.DOI:10.1038/ncb1725. [23] Del Conde I,Shrimpton CN,Thiagarajan P,et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation[J].Blood,2005,106(5):1604-1611.DOI:10.1182/blood-2004-03-1095. [24] Brat DJ,Bellail AC,Van Meir EG.The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis[J].Neuro Oncol,2005,7(2):122-133.DOI:10.1215/S1152851704001061. [25] Eberle K,Oberpichler A,Trantakis C,et al. The expression of angiogenin in tissue samples of different brain tumours and cultured glioma cells[J].Anticancer Res,2000,20(3A):1679-1684. [26] Rolhion C,Penault-Llorca F,Kémény JL,et al. Interleukin-6 overexpression as a marker of malignancy in human gliomas[J].J Neurosurg,2001,94(1):97-101.DOI:10.3171/jns.2001.94.1.0097. [27] Toustrup K,Sorensen BS,Nordsmark M,et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer[J].Cancer Res,2011,71(17):5923-5931.DOI:10.1158/0008-5472.CAN-11-1182. [28] Azmi AS,Bao B,Sarkar FH.Exosomes in cancer development,metastasis,and drug resistance:a comprehensive review[J].Cancer Met Rev,2013,32(3-4):623-642.DOI:10.1007/s10555-013-9441-9. [29] Shao HL,Chung J,Lee K,et al. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma[J].Nat Commun,2015,6:6999.DOI:10.1038/ncomms7999. [30] Wang Z,Chen JQ,Liu JL,et al. Exosomes in tumor microenvironment:novel transporters and biomarkers[J].J Transl Med,2016,14:297.DOI:10.1186/s12967-016-1056-9. [31] Elsner L,Muppala V,Gehrmann M,et al. The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands[J].J Immunol,2007,179(8):5523-5533.DOI:10.4049/jimmunol.179.8.5523. [32] Chalmin F,Ladoire S,Mignot G,et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells[J].J Clin Invest,2010,120(2):457-471.DOI:10.1172/JCI40483. [33] Zhao L,Liu WT,Xiao J,et al. The role of exosomes and"exosomal shuttle microRNA" in tumorigenesis and drug resistance[J].Cancer Lett,2015,356(2):339-346.DOI:10.1016/j.canlet.2014.10.027. [34] Szczepanski MJ,Szajnik M,Welsh A,et al. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-Β1[J].Haematologica,2011,96(9):1302-1309.DOI:10.3324/haematol.2010.039743. [35] Clayton A,Mitchell JP,Court J,et al. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2[J].Cancer Res,2007,67(15):7458-7466.DOI:10.1158/0008-5472.CAN-06-3456. [36] Akers JC,Ramakrishnan V,Kim R,et al. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF):a platform for glioblastoma biomarker development[J/OL].PLoS One,2013,8(10):e78115.DOI:10.1371/journal.pone.0078115. [37] Shi R,Wang PY,Li XY,et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients[J].Oncotarget,2015,6(29):26971-26981.DOI:10.18632/oncotarget.4699. [38] Alvarez-Erviti L,Seow Y,Yin HF,et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes[J].Nat Biotechnol,2011,29(4):341-345.DOI:10.1038/nbt.1807. [39] Kooijmans SAA,Vader P,Van Dommelen SM,et al. Exosome mimetics:a novel class of drug delivery systems[J].Int J Nanomedicine,2012,7:1525-1541.DOI:10.2147/IJN.S29661. [40] Li YH,Wang J,Wientjes MG,et al. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor[J].Adv Drug Deliv Rev,2012,64(1):29-39.DOI:10.1016/j.addr. 2011.04.006. [41] Munoz JL,Bliss SA,Greco SJ,et al. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity[J].Mol Ther Nucleic Acids,2013,2:e126.DOI:10.1038/mtna.2013.60. [42] Bu N,Wu HQ,Sun BZ,et al. Exosome-loaded dendritic cells elicit tumor-specific 8+ cytotoxic T cells in patients with glioma[J].J Neurooncol,2011,104(3):659-667.DOI:10.1007/s11060-011-0537-1. [43] Zhuang XY,Xiang XY,Grizzle W,et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain[J].Mol Ther,2011,19(10):1769-1779.DOI:10.1038/mt.2011.164. [44] Katakowski M,Buller B,Zheng XG,et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth[J].Cancer Lett,2013,335(1):201-204.DOI:10.1016/j.canlet.2013.02.019. [45] Graner MW,Alzate O,Dechkovskaia AM,et al. Proteomic and immunologic analyses of brain tumor exosomes[J].FASEB J,2009,23(5):1541-1557.DOI:10.1096/fj.08-122184. [46] Sáenz-Cuesta M,Osorio-Querejeta I,Otaegui D.Extracellular vesicles in multiple sclerosis:what are they telling us?[J].Front Cell Neurosci,2014,8:100.DOI:10.3389/fncel.2014.00100. [47] Grapp M,Wrede A,Schweizer M,et al. Choroid plexus transcytosis and exosome shuttling deliver folate into brain parenchyma[J].Nat Commun,2013,4:2123.DOI:10.1038/ncomms3123. [48] Haqqani AS,Delaney CE,Tremblay TL,et al. Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells[J].Fluids Barriers CNS,2013,10(1):4.DOI:10.1186/2045-8118-10-4. [49] Koyama Y,Ito T,Hasegawa A,et al. Exosomes derived from tumor cells genetically modified to express mycobacterium tuberculosis antigen:a novel vaccine for cancer therapy[J].Biotechnol Lett,2016,38(11):1857-1866.DOI:10.1007/s10529-016-2185-1. [50] Besse B,Charrier M,Lapierre V,et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC[J].Oncoimmunology,2016,5(4):e1071008.DOI:10.1080/2162402X.2015.1071008. [51] Dai SM,Wei D,Wu Z,et al. Phase Ⅰ clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer[J].Mol Ther,2008,16(4):782-790.DOI:10.1038/mt.2008.1. [52] Navabi H,Croston D,Hobot J,et al. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial[J].Blood Cells Mol Dis,2005,35(2):149-152.DOI:10.1016/j.bcmd.2005.06.008. [53] Escudier B,Dorval T,Chaput N,et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes:results of thefirst phase Ⅰ clinical trial[J].J Transl Med,2005,3(1):10.DOI:10.1186/1479-5876-3-10. [54] Bloch O,Crane CA,Fuks Y,et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma:a phase Ⅱ,single-arm trial[J].Neuro Oncol,2014,16(2):274-279.DOI:10.1093/neuonc/not203. [55] Han SJ,Zygourakis C,Lim M,et al. Immunotherapy for glioma:promises and challenges[J].Neurosurg Clin N Am,2012,23(3):357-370.DOI:10.1016/j.nec.2012.05.001. [56] Crane CA,Han SJ,Ahn B,et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein[J].Clin Cancer Res,2013,19(1):205-214.DOI:10.1158/1078-0432.CCR-11-3358. [57] Sayegh ET,Oh T,Fakurnejad S,et al. Vaccine therapies for patients with glioblastoma[J].J Neurooncol,2014,119(3):531-546.DOI:10.1007/s11060-014-1502-6.
2018, Vol. 27 
